Helicos' Q2 Revenues Rise 78 Percent as Cash Dwindles | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Helicos BioSciences' revenues for the second quarter rose 78 percent as grant revenues increased by 170 percent, the company disclosed in a document filed with the US Securities and Exchange Commission after the close of the market on Monday.

For the three months ended June 30, total revenues bounced to $661,000 from $371,000 a year ago. While product revenue dropped to $85,000 from $158,000 in Q2 2009, grant revenues shot up to $576,000 from $213,000 year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.